Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$7,593,732
-$135,882 QoQ
Shares Held
224,070
-7.2% QoQ
Ownership
0.187%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#54
of 197 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GILDER GAGNON HOWE & CO LLC holds $353,222,516 across 21 Biotechnology names. NAMS ranks #11 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
269,051 | $80,992,422 | |
| 2 | NKTR |
Nektar Therapeutics
|
600,873 | $41,946,944 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
548,926 | $40,884,008 | |
| 4 | ARQT |
Arcutis Biotherapeutics, Inc.
|
1,313,211 | $34,432,392 | |
| 5 | CYTK |
Cytokinetics Inc
|
400,245 | $34,096,871 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
229,053 | $26,265,507 | |
| 7 | QURE |
uniQure N.V.
|
530,979 | $24,456,892 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
28,573 | $15,342,272 |
All Filings in NAMS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,593,732 | 224,070 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $7,729,614 | 241,475 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $8,718,362 | 248,528 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,034,760 | 36,384 | Shares | Sole | 2025-11-14 | |
| 2025-03-31 | $605,277 | 29,569 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $767,684 | 29,871 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $397,105 | 23,922 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $468,435 | 24,385 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $578,620 | 24,466 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||